Jazz Pharmaceuticals plc — Director's Dealing 2024

Mar 8, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2024-03-05

Reporting Person: Iannone Robert (EVP, Global Head of R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-03-05	Ordinary Shares	F	4294	$117.53	Disposed	62226	Direct

Footnotes

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.